Abbott Laboratories
100 Abbott Park Road
Abbott Park
Illinois
United States
About Abbott Laboratories
1466 articles about Abbott Laboratories
-
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
3/5/2023
Abbott announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation, that demonstrate long-term benefits of the device in patients battling heart failure.
-
New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
3/4/2023
Abbott announced late-breaking data for the TriClip™ transcatheter edge-to-edge repair system, a first-of-its-kind minimally invasive device designed specifically for tricuspid heart valve repair.
-
Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices
2/28/2023
Abbott (NYSE: ABT) today announced late-breaking data for its next-generation Navitor™ transcatheter aortic valve implantation (TAVI) system.
-
Abbott Declares 397th Consecutive Quarterly Dividend
2/17/2023
The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.
-
Abbott to Acquire Cardiovascular Systems, Inc.
2/8/2023
Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
-
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
1/17/2023
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
-
Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation
1/7/2023
The mixed reality technology is an immersive digital experience designed to improve the blood donation process, attract new donors and motivate a younger generation to give blood.
-
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany
12/21/2022
Abbott (NYSE: ABT) today announced that its FreeStyle Libre® 3 sensor is now compatible with the mylife™ Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data.
-
Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain
12/19/2022
Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.
-
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
12/9/2022
This marks the company's 51st consecutive year of dividend growth. It will be the 396th consecutive quarterly dividend to be paid by Abbott since 1924.
-
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
11/17/2022
Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
-
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
10/28/2022
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre® continuous glucose monitoring technology as the "Best Medical Technology" of the last 50 years during its Prix Galien Golden Jubilee Awards ceremony on Oct. 27 in New York City.
-
Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.
-
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
10/7/2022
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period").
-
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies
9/17/2022
Abbott announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases.
-
Abbott Declares 395th Consecutive Quarterly Dividend
9/15/2022
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share.
-
Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery
9/8/2022
Abbott announced three-year data showing the positive impact of the Amplatzer Piccolo™ Occluder on treating babies with a potentially life-threatening hole in the heart known as a patent ductus arteriosus.
-
New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
8/29/2022
Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease.
-
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
-
FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions
8/23/2022
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim™ Plus spinal cord stimulation (SCS) system featuring FlexBurst360™ therapy.